Talis Biomedical Corp
Talis Biomedical Corporation does not have significant operations. Previously, it was involved in the development of medical devices for infectious diseases and other conditions at the point of care in the United States. The company evaluates strategic alternatives, including acquisition, merger, reverse merger, divestiture of assets, a voluntary reorganization, dissolution or liquidation, and li… Read more
Talis Biomedical Corp (TLIS) - Net Assets
Latest net assets as of June 2024: $48.63 Million USD
Based on the latest financial reports, Talis Biomedical Corp (TLIS) has net assets worth $48.63 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($72.70 Million) and total liabilities ($24.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $48.63 Million |
| % of Total Assets | 66.89% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 0.18 |
Talis Biomedical Corp - Net Assets Trend (2018–2023)
This chart illustrates how Talis Biomedical Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Talis Biomedical Corp (2018–2023)
The table below shows the annual net assets of Talis Biomedical Corp from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $69.12 Million | -45.47% |
| 2022-12-31 | $126.74 Million | -45.83% |
| 2021-12-31 | $233.98 Million | +315.51% |
| 2020-12-31 | $-108.57 Million | -413.58% |
| 2019-12-31 | $-21.14 Million | +59.35% |
| 2018-12-31 | $-52.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Talis Biomedical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48565900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $609.08 Million | 881.24% |
| Total Equity | $69.12 Million | 100.00% |
Talis Biomedical Corp Competitors by Market Cap
The table below lists competitors of Talis Biomedical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
X2M Connect Ltd
AU:X2M
|
$2.05 Million |
|
JET CONTRACTORS
BC:JET-CONTRACTORS
|
$2.05 Million |
|
Oxford Cannabinoid Technologies Holdings Plc
PINK:OCTHF
|
$2.05 Million |
|
PExA AB (publ)
F:FA0
|
$2.05 Million |
|
CARLSON INV. ZY 13
F:2HB
|
$2.04 Million |
|
GECI International SA
PA:ALGEC
|
$2.04 Million |
|
AEMLF
PINK:AEMLF
|
$2.04 Million |
|
Eastern Resources Ltd
AU:EFE
|
$2.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Talis Biomedical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 126,739,000 to 69,116,000, a change of -57,623,000 (-45.5%).
- Net loss of 62,007,000 reduced equity.
- Other factors increased equity by 4,384,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-62.01 Million | -89.71% |
| Other Changes | $4.38 Million | +6.34% |
| Total Change | $- | -45.47% |
Book Value vs Market Value Analysis
This analysis compares Talis Biomedical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-23.05 | $1.56 | x |
| 2019-12-31 | $-5.94 | $1.56 | x |
| 2020-12-31 | $-374.38 | $1.56 | x |
| 2021-12-31 | $154.95 | $1.56 | x |
| 2022-12-31 | $71.38 | $1.56 | x |
| 2023-12-31 | $38.03 | $1.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Talis Biomedical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15050.24%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.37x
- Recent ROE (-89.71%) is below the historical average (-43.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -892.76% | 0.21x | 0.00x | $-16.14 Million |
| 2019 | 0.00% | -689.77% | 0.15x | 0.00x | $-25.32 Million |
| 2020 | 0.00% | -832.66% | 0.06x | 0.00x | $-80.22 Million |
| 2021 | -81.40% | -2325494505.49% | 0.00x | 1.14x | $-213.86 Million |
| 2022 | -87.49% | -3036.28% | 0.02x | 1.34x | $-123.56 Million |
| 2023 | -89.71% | -15050.24% | 0.00x | 1.37x | $-68.92 Million |
Industry Comparison
This section compares Talis Biomedical Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Talis Biomedical Corp (TLIS) | $48.63 Million | 0.00% | 0.50x | $2.04 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |